460 related articles for article (PubMed ID: 33140542)
1. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.
Kim SH; Abbasi F; Nachmanoff C; Stefanakis K; Kumar A; Kalra B; Savjani G; Mantzoros CS
Diabetes Obes Metab; 2021 Feb; 23(2):489-498. PubMed ID: 33140542
[TBL] [Abstract][Full Text] [Related]
2. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.
Stefanakis K; Kokkinos A; Argyrakopoulou G; Konstantinidou SK; Simati S; Kouvari M; Kumar A; Kalra B; Kumar M; Bontozoglou N; Kyriakopoulou K; Mantzoros CS
Diabetes Obes Metab; 2023 Sep; 25(9):2561-2574. PubMed ID: 37246799
[TBL] [Abstract][Full Text] [Related]
3. Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial.
Perakakis N; Kalra B; Angelidi AM; Kumar A; Gavrieli A; Yannakoulia M; Mantzoros CS
Metabolism; 2022 Apr; 129():155157. PubMed ID: 35114286
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of five proglucagon-derived peptides in response to intravenous or oral glucose or lipids and to a mixed-meal in subjects with normal weight, overweight, and obesity.
Perakakis N; Kokkinos A; Angelidi AM; Tsilingiris D; Gavrieli A; Yannakoulia M; Tentolouris N; Mantzoros CS
Clin Nutr; 2022 Sep; 41(9):1969-1976. PubMed ID: 35961260
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels of all proglucagon-derived peptides are differentially regulated postprandially by obesity status and in response to high-fat meals vs. high-carbohydrate meals.
Stefanakis K; Kokkinos A; Simati S; Argyrakopoulou G; Konstantinidou SK; Kouvari M; Kumar A; Kalra B; Mantzoros CS
Clin Nutr; 2023 Aug; 42(8):1369-1378. PubMed ID: 37418844
[TBL] [Abstract][Full Text] [Related]
6. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
[TBL] [Abstract][Full Text] [Related]
7. GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr
Patel A; Yusta B; Matthews D; Charron MJ; Seeley RJ; Drucker DJ
Mol Metab; 2018 Oct; 16():45-54. PubMed ID: 29937214
[TBL] [Abstract][Full Text] [Related]
8. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
[TBL] [Abstract][Full Text] [Related]
10. Proglucagon-Derived Peptides as Therapeutics.
Lafferty RA; O'Harte FPM; Irwin N; Gault VA; Flatt PR
Front Endocrinol (Lausanne); 2021; 12():689678. PubMed ID: 34093449
[TBL] [Abstract][Full Text] [Related]
11. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
Drucker DJ
Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):22-31. PubMed ID: 16929363
[TBL] [Abstract][Full Text] [Related]
12. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.
Roberge JN; Brubaker PL
Endocrinology; 1993 Jul; 133(1):233-40. PubMed ID: 8319572
[TBL] [Abstract][Full Text] [Related]
13. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A; Kapitza C; Hindsberger C; Zdravkovic M
Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
[TBL] [Abstract][Full Text] [Related]
14. Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition.
Streckel E; Braun-Reichhart C; Herbach N; Dahlhoff M; Kessler B; Blutke A; Bähr A; Übel N; Eddicks M; Ritzmann M; Krebs S; Göke B; Blum H; Wanke R; Wolf E; Renner S
J Transl Med; 2015 Feb; 13():73. PubMed ID: 25890210
[TBL] [Abstract][Full Text] [Related]
15. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
16. Enteroglucagon.
Holst JJ
Annu Rev Physiol; 1997; 59():257-71. PubMed ID: 9074764
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day].
Sklyanik IA; Shestakova MV
Ter Arkh; 2021 Oct; 93(10):1203-1208. PubMed ID: 36286822
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
Kim SH; Liu A; Ariel D; Abbasi F; Lamendola C; Grove K; Tomasso V; Reaven G
Diabetologia; 2014 Mar; 57(3):455-62. PubMed ID: 24326527
[TBL] [Abstract][Full Text] [Related]
19. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
Maida A; Lovshin JA; Baggio LL; Drucker DJ
Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
[TBL] [Abstract][Full Text] [Related]
20. Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion.
Hui H; Yu R; Bousquet C; Perfetti R
Endocrinology; 2002 Sep; 143(9):3529-39. PubMed ID: 12193567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
